Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Por um escritor misterioso
Descrição
Peptides for Vaccine Development
Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines - Sette - 2022 - Immunological Reviews - Wiley Online Library
COVID-19 in patients with hematologic malignancy - ScienceDirect
SARS-CoV-2 Vaccine Development: An Overview and Perspectives
Frontiers Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response
Cancers, Free Full-Text
COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study - The Lancet Oncology
Cancer in the Midst of COVID-19, A Report
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study - The Lancet Rheumatology
State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation
Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
de
por adulto (o preço varia de acordo com o tamanho do grupo)
